Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib + Dasatinib + Prednisone + Blinatumomab in Ph+ ALL/CML
NCT03595917Phase 1Recruiting
- Start
- Jul 2018
- Primary completion
- Nov 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of asciminib in acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). Primary endpoint: Maximum Tolerated Dose of ABL001 at 42 Days. Started Jul 2018; status: recruiting.
02
Drugs
asciminib
03
Conditions
acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03595917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595917.